ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

Monica Margoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.